Literature DB >> 21346249

Different role of CD73 in leukocyte trafficking via blood and lymph vessels.

Annika Ålgars1, Marika Karikoski, Gennady G Yegutkin, Patrizia Stoitzner, Jussi Niemelä, Marko Salmi, Sirpa Jalkanen.   

Abstract

CD73 is involved in the extracellular ATP metabolism by dephosphorylating extracellular AMP to adenosine and thus regulating permeability of the blood vessels and leukocyte traffic into the tissues. It is also present on lymphatic vessels where its distribution and function have not been characterized. We found that CD73 is expressed on a subpopulation of afferent lymph vessels but is absent on efferent lymphatics, unlike LYVE-1 and podoplanin, which are expressed on both types of lymphatics. The extracellular nucleotide metabolism on lymphatic endothelium differs from that on blood vessel endothelium as lymphatic endothelium has lower NTPDase and higher ecto-5'-nucleotidase/CD73 activity than blood vascular endothelium. In knockout mice, the lack of CD73 on lymphocytes decreases migration of lymphocytes to the draining lymph nodes more than 50% while CD73-deficient lymph vessels mediate lymphocyte trafficking as efficiently as the wild-type lymphatics. Thus, although endothelial CD73 is important for permeability and leukocyte extravasation in blood vessels, it does not have a role in these functions on lymphatics. Instead, lymphocyte CD73 is intimately involved in lymphocyte migration via afferent lymphatic vessels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346249     DOI: 10.1182/blood-2010-11-321646

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  CD73 promotes tumor growth and metastasis.

Authors:  Bin Zhang
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 2.  Ectoenzymes in leukocyte migration and their therapeutic potential.

Authors:  Marko Salmi; Sirpa Jalkanen
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

3.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

4.  Gene-expression profiling of different arms of lymphatic vasculature identifies candidates for manipulation of cell traffic.

Authors:  Imtiaz Iftakhar-E-Khuda; Ruth Fair-Mäkelä; Anu Kukkonen-Macchi; Kati Elima; Marika Karikoski; Pia Rantakari; Masayuki Miyasaka; Marko Salmi; Sirpa Jalkanen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

5.  Distinctive immunoregulatory effects of adenosine on T cells of older humans.

Authors:  Charles S Hesdorffer; Enkhzol Malchinkhuu; Arya Biragyn; Omar S Mabrouk; Robert T Kennedy; Karen Madara; Dennis D Taub; Dan L Longo; Janice B Schwartz; Luigi Ferrucci; Edward J Goetzl
Journal:  FASEB J       Date:  2011-11-25       Impact factor: 5.191

6.  Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma.

Authors:  Y I Yu; Wei Wang; Lei Song; Wentao Hu; Chi Dong; Hailong Pei; Guangming Zhou; Zhongjin Yue
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

Review 7.  The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).

Authors:  T L Whiteside; M Mandapathil; P Schuler
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 8.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

9.  5'-AMP impacts lymphocyte recirculation through activation of A2B receptors.

Authors:  Hjalmar R Bouma; Judith N Mandl; Arjen M Strijkstra; Ate S Boerema; Jan-Willem Kok; Annie van Dam; Ad Ijzerman; Frans G M Kroese; Robert H Henning
Journal:  J Leukoc Biol       Date:  2013-05-16       Impact factor: 4.962

Review 10.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.